{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-022227","form_type":"8-K","ticker":"HROW","cik":"0001360214","company_name":"HARROW, INC.","filed_at":"2026-05-11T20:10:43+00:00","discovered_at":"2026-05-11T20:12:00.323223+00:00","generated_at":"2026-05-11T22:19:08.053982+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Harrow Q1 revenue $44.2M, net loss $27.6M; VEVYE market share reaches 14%","bullets":["Revenue of $44.2M, down 8% YoY, including ~$8M non-recurring gross-to-net adjustment related to new VEVYE commercial coverage.","Net loss of $27.6M ($0.74 diluted EPS) vs. loss of $17.8M ($0.50) in Q1 2025; Adjusted EBITDA -$12.7M.","VEVYE delivered record quarterly prescriptions: NRx +25% QoQ, TRx +11% QoQ; surpassed XIIDRA on monthly TRx with ~14% market share.","IHEEZO unit demand +18% YoY to 45,509 units (82% from retina); TRIESENCE unit demand +136% YoY for 6th consecutive growth quarter.","Q2 2026 revenue guidance $71M-$81M; full-year 2026 revenue reaffirmed $350M-$365M, Adjusted EBITDA $80M-$100M."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-022227","json":"https://secwatch.observer/filing/0001493152-26-022227.json","markdown":"https://secwatch.observer/filing/0001493152-26-022227.md","text":"https://secwatch.observer/filing/0001493152-26-022227.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1360214/000149315226022227/0001493152-26-022227-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1360214/000149315226022227/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T22:19:08.053982+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5ab6de9d128c511a2c9d618eb36540672cfbedd0","claim":"HARROW, INC. reported quarter ended March 31, 2026 results: revenue $44,203,000, net income Net loss $(27,602,000), EPS $(0.74). Guidance reaffirmed.","evidence_excerpt":"Total revenues $ 44,203,000 $ 47,831,000 Gross margin 61 % 68 % Net loss (27,602,000 ) (17,780,000 ) Adjusted EBITDA (1) (12,659,000 ) (1,985,000 ) Net loss per share, basic and diluted (0.74 ) (0.50 )","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1360214/000149315226022227/0001493152-26-022227-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2026"},{"label":"Revenue","value":"$44,203,000"},{"label":"Net income","value":"Net loss $(27,602,000)"},{"label":"EPS","value":"$(0.74)"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}